In Episode 88 of The Weekly Bioanalysis, hosts Dominic Warrino and John Perkins present a special WRIB 2025 recap featuring several KCAS Bio scientists who share firsthand insights from their presentations at the major bioanalytical conference. Dave Ambrose highlights KCAS Bio’s global harmonization of spectral flow cytometry instruments across sites in the U.S., France, and Australia, showcasing the industry’s first off-the-shelf spectral flow panel with impressively tight inter-site CVs. Jessica Pham discusses her work on a VAMS-based PK assay for an anti-malarial monoclonal antibody, designed to enable microsampling in remote regions with high temperature stability. Bryan Parmentier presents a novel method for overcoming matrix effects in cisplatin assays by adding exogenous hemoglobin, a breakthrough inspired by clinical anemia observations. The episode concludes with a group discussion about the implications of new biomarker guidance from the FDA and ICH M10, sparking debate on validation standards, regulatory interpretations, and industry alignment.

“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.

KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

In episode 87 of The Weekly Bioanalysis podcast, John Perkins and Dawn Dufield preview the upcoming WRIB conference, where KCAS Bio and Sciex will both have strong representation through scientific presentations, panels, and business development efforts. Special guest, Rahul Baghla of Sciex, discusses the company’s collaboration with KCAS Bio and introduces their high-throughput Echo technology, which uses acoustic ejection to improve speed and reduce carryover in early discovery assays. The conversation explores the evolution of mass spectrometry platforms, highlighting the robustness and sensitivity of Sciex’s 7500+ system and the increasing role of AI in streamlining data analysis. Dawn and John reflect on the challenges of adopting new technologies in regulated environments, emphasizing the balance between innovation and practical application.

“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.

KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

During episode 86 of KCAS Bio's "The Weekly Bioanalysis" podcast, our hosts Dom and John are joined by Dr Cheikh Kane, the Vice President of Biopharma Services at KCAS Bio, to discuss immunogenicity. They first define Immunogenicity; what it is and why it is tested, as well as the standard approach for ADA testing before answering the question of "What is a 'Lean' anti-drug antibody (ADA) approach, and when should it be employed?". Dr Kane brings his decades of experience and biopharmaceutical expertise to a very impressive conversation that showcases the many options involved in ADA testing. This is one you won't want to miss!

“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.

KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

Dom and John, the hosts of “The Weekly Bioanalysis”, recently returned from EBF in Barcelona where there was a session on Patient-centric Microsampling, which both of them founnd fascinating. This inspired both of them to decide it was high time to revisit this part of our industry. In spite of a few infamous setbacks caused by the dishonesty of a few bad actors within the industry a years ago, there has been a renewed interest in patient-centric sampling, and our hosts have invited one of the pioneers in this field, Dr Neil Spooner, to join them on episode #85 to discuss the recent advances in the reemerging science around microsampling. They discuss Dried Blood Spot Analysis, device-based sampling vs conventional assays, the devices currently available, and what all of this might mean for the future of bioanalysis.

“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.

KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and how the evolving role of LC-MS continues to shape the industry. Parmentier emphasizes the value of pre-validation in ensuring method robustness and shares lessons learned from developing methods for antibody-drug conjugate (ADC) payloads. He also details the revised KCAS Bio approach for method development of ADC payloads and the associated downstream validation experiments. This episode provides valuable insights for professionals involved in bioanalysis, particularly in the context of complex analytes and cutting-edge therapeutics.

“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.

KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

The 2024 tradeshow and conference season is finally coming to a close for the pharmaceutical and biotech industry, and our road-weary traveling hosts, Dom and John have returned from their final event, the 2024 European Bioanalysis Forum (EBF) Open Symposium in Barcelona, Spain. EBF was founded in 2006 at the initiative of 12 pharmaceutical companies. The goal was to create a platform for discussions around science, day-to-day procedures, business tools, technologies and - last but not least - regulatory issues. The theme of the conference this year was “Taking the temperature of bioanalysis”, which is exactly what the guys have come back to discuss here for the 83rd episode of “The Weekly Bioanalysis” podcast!

“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.

KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

It’s conference season! This is a busy, busy time of the year for the entire industry, when everyone comes together from around the world to share, listen and discuss the changes and advancements taking place in the business and science of the pharma and biotech space. During this episode of “The Weekly Bioanalysis”, our hosts, Dom and John, go over all the places – around the world – where the KCAS Bio team will be taking part in exhibitions, panels and presentations. From Europe to Australia and all over the U.S., KCAS Bio will be attending a number of events, conferences and trade shows, featuring all the great things our organization has been up to over the last year or so. There is so much to go over, and we hope to see you at many of these industry events!

“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.

KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.

After such a great response to our recent episode on the topic, our hosts, Dom and John, revisit the topic of GLP-1 Analogue development and the role bioanalysis plays in this relatively new and popular topic. In the words of John, “Everyone else is talking about this; why shouldn’t we?” And wow, do they have a lot to say about it on this second pass at the advances being made in this ever-growing and ever-changing field. The guys talk about the latest developments in the GLP-1 Analogue space, KCAS Bio’s experience with GLP-1 Analogs, options when choosing the right technology for these studies, some of the challenges associated with the LC-MS Approach, the options available around Ligand Binding Assays for GLP-1 Analogues in tissues, and whether there may even be value in conversation about a Hybrid LC-MS approach!

“The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio.

KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.